Drug Search Results
More Filters [+]

Romidepsin

Alternative Names: romidepsin, istodax, fk228, depsipeptide, fr901228
Latest Update: 2024-05-20
Latest Update Note: Clinical Trial Update

Product Description

Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi). It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a promising drug for the treatment of T-cell lymphomas. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28641053/)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Canada | European Medicines Agency | Greece | Israel | Japan | United States

Approved Indications: Lymphoma | T-Cell Cutaneous Lymphoma | T-Cell Lymphoma

Known Adverse Events: Anemia | Lymphopenia | Thrombocytopenia | Neutropenia | Anorexia

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Romidepsin

Countries in Clinic: Belgium, France, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: T-Cell Peripheral Lymphoma

Phase 2: HIV Infections|Large-Cell Anaplastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|T-Cell Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PTCL

P2

Recruiting

T-Cell Peripheral Lymphoma

2026-06-02

SYNACTHIV

P1

Recruiting

HIV Infections

2026-04-15

NCT01755975

P2

Completed

Multiple Myeloma|Lymphoma, Non-Hodgkin

2023-10-01

Ro-CHOP_study

P3

Completed

T-Cell Peripheral Lymphoma

2022-12-13

Recent News Events